Anti-Progesterone Receptor (Ser294) Antibody

There is accumulating evidence to suggest that progesterone plays an essential role in the regulation of growth and differentiation of mammary glands and thus may play a key role in breast cancer (Edwards, 2005) . The biological response to progesterone is mediated by two distinct forms of the human progesterone receptor (PR-A and PR-B forms) . In most cell contexts, the B form functions as a transcriptional activator, whereas the A form functions as a transcriptional inhibitor of steroid hormones (Attia et al., 2000; Lin et al., 2003) . Recently it has been demonstrated that there is differential hormone dependent regulation of the phosphorylation of the A and B forms of the receptor (Clemm et al., 2000) . Treatment of T47D breast cancer cells with progestin agonist increases the phosphorylation of Ser-190 and Ser-294 with different kinetics. These phosphorylation events may differentially affect the transcriptional activity of the receptor.

NR3C3 antibody, Nuclear receptor subfamily 3 group C member 3 antibody, PGR antibody, PR antibody, PRA antibody, PRB antibody, PRGR_HUMAN antibody, Progesterone receptor antibody, Progestin receptor form A antibody, Progestin receptor form B antibody

For research use only. Not intended for therapeutic or diagnostic use. Use of all products is subject to our terms and conditions, which can be viewed on our website.

Synthetic phospho-peptide corresponding to amino acid residues surrounding Ser294 of human progesterone receptor, conjugated to keyhole limpet hemocyanin (KLH) .

Specific for endogenous levels of the ~90 kDa PR-A isoform and the ~120 kDa PR-B isoform phosphorylated at Ser294. Immunolabeling is blocked by preadsorption with the phosphopeptide used as antigen, but not by the corresponding non-phosphopeptide.